Real-word Assessment of the Clinical Characteristics and Adherence to the European Society of Cardiology Guideline-Directed Medical Therapies in Heart Failure Care Management in France: REMOTE-HF Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17,551
- 试验地点
- 1
- 主要终点
- To evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients.
研究概览
简要总结
The goal of this observational study was to evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients from 2021 to 2024, particularly in relation to LVEF subgroups and evolving scientific evidence (EMPEROR-Preserved, DELIVER, 2023 Guidelines).
Participant population were adults with heart failure using the Satelia®Cardio web application to remotely monitor their condition.
The main questions it aims to answer are:
- to compare the prescription of treatments (including doses, and distribution of patients according to various therapeutic classes recommend for heart failure) with ESC recommendations to see to what extent GDMTs are adhered to.
- to quantify the association between the presence of treatments and the risk of alerts/hospitalizations and overall death and as a function of LVEF using telemonitoring.
- to evaluate the adherence across patient profiles and cardiologist practices (outpatient vs. hospital-based).
Participants will complete follow-up, quality-of-life and patient support questionnaires and provide data regarding their treatments on the web application.
详细描述
A retrospective, multicenter descriptive study was conducted in France from January 1, 2021 to December 31, 2024. The REMOTE-HF study included 17,551 patients enrolled in remote monitoring program for heart failure (HF) management. We described and analyzed the implementation of ESC guidelines in patients monitored remotely with a web application named Satelia®Cardio (NP Medical).
Key clinical parameters such as age, gender, NYHA class, LVEF, and HF etiology were analyzed. Prescribed therapies including ACEi/ARB/ARNis, beta-blockers, MRAs, and SGLT2 inhibitors, were compared against the European Society of Cardiology (ESC) guideline-directed medical therapies (GDMTs).
Adherence was evaluated across patient profiles and cardiologist practices (outpatient vs. hospital-based) in France.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 105 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •registered to use Satelia®Cardio to remotely monitor their condition
- •patients diagnosed with heart failure whatever the aetiology:
- •Especially patients who undergone:
- •Hospitalization within the previous 12 months, OR patients with NYHA class II or more, and BNP > 100 pg/ml OR NT-proBNP > 1000 pg/ml.
排除标准
- •People aged under 18 years old
- •Pregnant women
- •Physical or psychological impossibility for the patient or carer to use the digital medical device according to the judgment of the doctor wishing to include the patient in the remote medical monitoring project.
结局指标
主要结局
To evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients.
时间窗: From January 2021 to December 2024.
次要结局
未报告次要终点
研究者
Sophie NISSE-DURGEAT
Nicolas Girerd
Satelia